StemX Bio Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $486K

  • Investors
  • 7

StemX Bio General Information

Description

Developer of human pancreatic microtissues designed to accelerate early drug discovery and development. The company's features robust, reproducible microtissues derived from human stem cells, incorporating key pancreatic cell types for high-throughput screening, enabling researchers to reduce false positives, streamline drug testing, and advance diabetes research with improved physiological relevance and ethical integrity.

Contact Information

Website
www.stemxbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Biopartner 3, Galileiweg 8
  • 2333 BE Leiden
  • Netherlands
+31 06
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Biopartner 3, Galileiweg 8
  • 2333 BE Leiden
  • Netherlands
+31 06

StemX Bio Timeline

20252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

StemX Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 01-Dec-2025 $486K Completed Startup
7. Early Stage VC 11-Jul-2025 Completed Product In Beta Test
6. Accelerator/Incubator 10-Apr-2025 Completed Product In Beta Test
5. Early Stage VC 18-Dec-2024 Completed Product In Beta Test
4. Debt - General 18-Dec-2024 Completed Product In Beta Test
3. Accelerator/Incubator 25-Apr-2024 Completed Startup
2. Accelerator/Incubator 01-Jan-2024 Completed Startup
1. University Spin-Out 01-Jan-2024 Completed Startup
To view StemX Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

StemX Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of human pancreatic microtissues designed to accelerate early drug discovery and development. The company's fe
Biotechnology
Leiden, Netherlands
8 As of 2026

Schlieren, Switzerland
 

Toulouse, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

StemX Bio Competitors (2)

One of StemX Bio’s 2 competitors is InSphero, a Private Equity-Backed company based in Schlieren, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
InSphero Private Equity-Backed Schlieren, Switzerland
Human Cell Design Venture Capital-Backed Toulouse, France
You’re viewing 2 of 2 competitors. Get the full list »

StemX Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

StemX Bio Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
EUREKA Eurostars Government
UNIIQ Venture Capital Minority
PLNT. Accelerator/Incubator
LifeSciences@Work Accelerator/Incubator
Leids Universitair Medisch Centrum University
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

StemX Bio FAQs

  • When was StemX Bio founded?

    StemX Bio was founded in 2024.

  • Where is StemX Bio headquartered?

    StemX Bio is headquartered in Leiden, Netherlands.

  • What is the size of StemX Bio?

    StemX Bio has 8 total employees.

  • What industry is StemX Bio in?

    StemX Bio’s primary industry is Biotechnology.

  • Is StemX Bio a private or public company?

    StemX Bio is a Private company.

  • What is StemX Bio’s current revenue?

    The current revenue for StemX Bio is .

  • How much funding has StemX Bio raised over time?

    StemX Bio has raised $502K.

  • Who are StemX Bio’s investors?

    EUREKA Eurostars, UNIIQ, PLNT., LifeSciences@Work, and Leids Universitair Medisch Centrum are 5 of 7 investors who have invested in StemX Bio.

  • Who are StemX Bio’s competitors?

    InSphero and Human Cell Design are competitors of StemX Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process